HB 7391 amends the Public Health Service Act to forbid the Secretary of HHS from entering into or enforcing manufacturer arrangements that require Federally Qualified Health Centers (FQHCs) to pay above the 340B ceiling price at the time they buy covered outpatient drugs. The bill also bars contractual designs that let manufacturers recover the difference later through rebates, chargebacks, or other reconciliations.
This is a targeted change to procurement mechanics inside the 340B program: it removes the common practice of point‑of‑sale overpayment followed by later reconciliation and makes the discounted price immediately effective at purchase. For FQHCs and their patients, the change reduces cash‑flow exposure and billing complexity; for manufacturers and supply‑chain partners, it forces operational and contractual adjustments and may affect how 340B discounts are administered in practice.
At a Glance
What It Does
The bill adds a new paragraph to section 340B(a) prohibiting the Secretary from entering into agreements with manufacturers that require a covered entity described in 340B(a)(4)(A) to pay more than the applicable 340B ceiling price at the point of purchase. It separately states that arrangements where an excess payment is followed by later reconciliation do not satisfy 340B requirements.
Who It Affects
Directly affects Federally Qualified Health Centers (the covered entities identified in 340B(a)(4)(A)), manufacturers of covered outpatient drugs, contract pharmacies and wholesalers that handle 340B transactions, and HHS when evaluating compliance of existing agreements.
Why It Matters
By forcing discounts to apply at point‑of‑sale, the bill changes how 340B discounts flow through the supply chain, reducing short‑term cash exposure for safety‑net providers but creating operational and contractual pressures for manufacturers, distributors, and pharmacies that currently rely on post‑sale reconciliation.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
HB 7391 inserts a narrowly focused rule into the 340B statute: FQHCs must not be required to pay more than the 340B ceiling price when they purchase covered outpatient drugs. The statutory text accomplishes this by directing that the Secretary may not enter into agreements with manufacturers that impose a purchase‑time price above the ceiling, and by clarifying that later reconciliation (rebates, chargebacks, reimbursements) cannot be used to justify an initial overpayment.
Practically, the bill changes a common commercial pattern. In many current 340B setups, a covered entity may be invoiced at a price above the ceiling at time of sale while the manufacturer and downstream partners handle adjustments after the fact.
HB 7391 eliminates that pathway for FQHCs: the discounted, ceiling‑price must be reflected in the transaction when the product changes hands or is invoiced.The bill takes effect on enactment and applies to purchases on or after that date; it also requires that HHS consider these rules when judging whether existing manufacturer agreements comply with section 340B(a). The text does not create an explicit private right of action, specify new enforcement mechanisms, or set civil penalties; it operates by constraining the Secretary’s authority to enter into or recognize noncompliant arrangements under the 340B framework.Operationally, stakeholders will need to adjust ordering, invoicing, verification, and reconciliation systems.
Manufacturers may need to alter distribution controls, wholesalers and contract pharmacies must change billing flows, and FQHCs will expect point‑of‑sale invoices that reflect the ceiling price. How HHS will monitor or audit compliance and how existing contractual commitments between manufacturers and intermediaries will be unwound are left to administrative practice rather than spelled out in the statute.
The Five Things You Need to Know
The bill adds paragraph (11) to 340B(a) forbidding the Secretary from agreeing to manufacturer arrangements that require covered FQHCs to pay more than the 340B ceiling price at purchase.
It expressly bars contractual structures where an FQHC pays more at purchase and the manufacturer later reconciles the difference by rebate, chargeback, or other payment.
The amendments take effect on enactment and apply to drugs purchased on or after that date.
HHS must apply the new rule when determining whether existing agreements meet 340B(a) requirements—potentially altering the compliance status of current contracts.
The protected covered entities are those identified in 340B(a)(4)(A) — primarily Federally Qualified Health Centers under the statute — not the broader universe of 340B participants.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Establishes the bill’s name as the "Community Health Center Drug Pricing Protection Act." This is purely identificatory; it signals the sponsor’s focus on community health centers (FQHCs) and frames later provisions' intent without changing substance.
Prohibit agreements that force purchase‑time prices above the 340B ceiling price
Adds a new paragraph (11) to section 340B(a) instructing that the Secretary may not enter into an agreement with a drug manufacturer under which a covered entity described in 340B(a)(4)(A) is required to pay, at the time of purchase, more than the applicable ceiling price. Mechanically, this converts a statutory discretion limit on the Secretary into a direct constraint on permissible 340B contracting practices affecting FQHCs.
No after‑the‑fact reconciliations to evade the rule
Clarifies that nothing in the amendment allows agreements where the covered entity pays in excess of the ceiling price at purchase and receives later reconciliation from the manufacturer. This closes a likely loophole and makes the prohibition functional rather than merely declarative, by targeting the common commercial practice of retroactive adjustments.
Immediate application to new purchases and consideration of existing agreements
States the amendment takes effect on enactment and applies to drugs purchased on or after that date, and directs HHS to take the change into account when determining whether existing agreements comply with 340B(a). The provision does not specify transition procedures or grandfathering protections; instead it folds the rule into HHS’s ongoing compliance assessments.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Federally Qualified Health Centers (FQHCs): They receive predictable, immediate discounts at purchase, reducing short‑term cash outlays and administrative burdens tied to chasing post‑sale reconciliations.
- Low‑income and uninsured patients served by FQHCs: Faster, verifiable discounting can improve clinic pharmacy operations and preserve access by reducing billing disputes that can delay dispensing.
- FQHC‑operated pharmacies and in‑house dispensaries: Upfront ceiling‑price invoices simplify accounting and reduce risk from delayed manufacturer reimbursements that can strain small clinic cash flows.
Who Bears the Cost
- Drug manufacturers: They must alter contracting and distribution processes to accommodate point‑of‑sale discounts and lose flexibility offered by post‑sale reconciliation mechanisms, potentially increasing administrative and compliance costs.
- Wholesalers and contract pharmacies: These intermediaries will need to reconfigure billing, verification, and chargeback procedures to ensure the selling price at invoice meets the ceiling price, which could raise operational costs or reduce willingness to serve 340B transactions.
- Health Resources and Services Administration (HRSA)/HHS: The agencies will face new compliance‑monitoring duties to certify manufacturer agreements and may need guidance, rulemaking, or auditing resources to assess whether arrangements satisfy the statutory point‑of‑purchase requirement.
Key Issues
The Core Tension
The bill balances two legitimate goals—guaranteeing immediate, reliable discounts to safety‑net clinics versus preserving manufacturers’ and distributors’ ability to manage complex supply chains through post‑sale reconciliation—and it forces a trade‑off between financial predictability for FQHCs and the commercial flexibility manufacturers use to prevent diversion and administratively smooth 340B operations.
The bill fixes a specific problem—FQHCs paying above‑ceiling amounts up front and waiting for adjustments—but it leaves key implementation mechanics unspecified. It does not describe how HHS will verify that every purchase invoice reflects the ceiling price, whether wholesalers must issue adjusted invoices, or how split billing through contract pharmacies should operate.
Those operational gaps will require guidance or rulemaking, and until HHS supplies it, stakeholders will face uncertainty about acceptable compliance steps.
Removing post‑sale reconciliation could produce unintended consequences. Manufacturers currently use reconciliation to manage distribution, prevent diversion, and reconcile complex supply‑chain flows; eliminating that tool for FQHCs may prompt manufacturers to restrict product availability, tighten distribution controls, or restructure 340B participation.
Those reactions could shrink the number of manufacturers willing to accommodate 340B transactional changes or shift burdens to smaller clinics and pharmacies. The statute also constrains the Secretary’s contractual discretion but creates no private enforcement mechanism or explicit penalties, leaving it unclear whether affected FQHCs would have a direct remedy if manufacturers or intermediaries fail to comply.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.